DE602004015995D1 - Polypeptid mit verbesserter cytosin-deaminase-aktivität - Google Patents

Polypeptid mit verbesserter cytosin-deaminase-aktivität

Info

Publication number
DE602004015995D1
DE602004015995D1 DE602004015995T DE602004015995T DE602004015995D1 DE 602004015995 D1 DE602004015995 D1 DE 602004015995D1 DE 602004015995 T DE602004015995 T DE 602004015995T DE 602004015995 T DE602004015995 T DE 602004015995T DE 602004015995 D1 DE602004015995 D1 DE 602004015995D1
Authority
DE
Germany
Prior art keywords
polypeptide
cytosine deaminase
deaminase activity
improved
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004015995T
Other languages
English (en)
Inventor
Philippe Erbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE602004015995D1 publication Critical patent/DE602004015995D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004015995T 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase-aktivität Active DE602004015995D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
PCT/IB2004/002505 WO2005007857A1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
DE602004015995D1 true DE602004015995D1 (de) 2008-10-02

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004015995T Active DE602004015995D1 (de) 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase-aktivität

Country Status (17)

Country Link
US (3) US7790445B2 (de)
EP (2) EP1649023B1 (de)
JP (1) JP4672659B2 (de)
KR (1) KR101062140B1 (de)
CN (1) CN1826410B (de)
AT (1) ATE405654T1 (de)
AU (1) AU2004257935B2 (de)
CA (1) CA2532783C (de)
CY (1) CY1110397T1 (de)
DE (1) DE602004015995D1 (de)
DK (1) DK1649023T3 (de)
ES (1) ES2311831T3 (de)
HK (2) HK1112024A1 (de)
IL (1) IL173158A (de)
PL (1) PL1649023T3 (de)
PT (1) PT1649023E (de)
WO (1) WO2005007857A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
TWI614342B (zh) 2007-07-03 2018-02-11 存斯精菱公司 禽類永生化細胞系
NZ592070A (en) * 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
EP2429579A1 (de) 2009-05-12 2012-03-21 Transgene SA Immortalisierte vogel-zelllinien und ihre verwendung
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
EP2527432A1 (de) * 2011-05-23 2012-11-28 Novozymes A/S Bidirektionaler Cytosin-Deaminase-codierender Selektionsmarker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
CA2943871A1 (en) 2014-04-10 2015-10-15 Transgene S.A. Poxviral oncolytic vectors
CA2954841A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
CN107949397A (zh) * 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CA3113965A1 (en) 2018-09-26 2020-04-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DE69426841T2 (de) 1993-02-16 2001-09-06 Onyx Pharma Inc Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
EP0804590A1 (de) * 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
ATE405654T1 (de) 2008-09-15
KR101062140B1 (ko) 2011-09-05
US20100330051A1 (en) 2010-12-30
PL1649023T3 (pl) 2009-01-30
US20100330031A1 (en) 2010-12-30
EP1649023B1 (de) 2008-08-20
ES2311831T3 (es) 2009-02-16
IL173158A0 (en) 2006-06-11
EP1649023A1 (de) 2006-04-26
CA2532783A1 (en) 2005-01-27
HK1112024A1 (en) 2008-08-22
PT1649023E (pt) 2008-11-20
US20070264235A1 (en) 2007-11-15
EP1897938A1 (de) 2008-03-12
JP4672659B2 (ja) 2011-04-20
EP1897938B1 (de) 2010-10-06
CA2532783C (en) 2013-09-17
US8257692B2 (en) 2012-09-04
EP1897938B9 (de) 2011-08-31
US7790445B2 (en) 2010-09-07
IL173158A (en) 2009-12-24
JP2006527994A (ja) 2006-12-14
HK1084150A1 (en) 2006-07-21
US8226954B2 (en) 2012-07-24
KR20060040697A (ko) 2006-05-10
AU2004257935A1 (en) 2005-01-27
CN1826410A (zh) 2006-08-30
CY1110397T1 (el) 2015-04-29
WO2005007857A1 (en) 2005-01-27
DK1649023T3 (da) 2008-10-06
CN1826410B (zh) 2011-10-26
AU2004257935B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
HK1084150A1 (en) Polypeptide having an improved cytosine deaminase activity
DE502005006284D1 (de) Keratin-bindende polypeptide
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
EA201200398A1 (ru) Полипептиды с оксидоредуктазной активностью и их применение
DK2327719T3 (da) Hybrid- og tandemekspression af neisseria-proteiner
CY1110028T1 (el) Πολυπεπτιδια για την επαγωγη προστατευτικης ανοσοαπαντησης εναντι του staphylococcus aureus
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
DE602006019050D1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
RU2011106744A (ru) Инсулин, стабилизированный галогеном
IN2014CN02050A (de)
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE497975T1 (de) Il-21-varianten
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
ATE414156T1 (de) Lipase-varianten
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
NO20051938L (no) Promoter til IL-18BP, dens fremstilling og anvendelse
SE0101519D0 (sv) Nucleic ACID
WO2003072733A3 (en) Modified bace
EP1467207A4 (de) Screening-verfahren
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition